Runx2 downregulation, migration and proliferation inhibition in melanoma cells treated with BEL β-trefoil

Massimiliano Perduca, Luca Dalle Carbonare, Michele Bovi, Giulio Innamorati, Samuele Cheri, Chiara Cavallini, Maria Teresa Scupoli, Antonio Mori, Maria Teresa Valenti
2017 Oncology Reports  
Malignant melanoma is a lethal form of skin cancer and highly metastatic tumor with poor prognosis; BEL β-trefoil, a lectin, obtained by our group, possesses the ability to act specifically on malignant cells. Therefore, the aim of our study was to investigate the effects of BEL β-trefoil in melanoma cells in an attempt to evaluate its potential usage as anticancer agent. BEL β-trefoil was purified by chromatography and A375 and MeWo melanoma cells were treated. Viability and proliferation were
more » ... proliferation were evaluated as well as apoptosis, RUNX2 gene expression and migration ability. The treated tumor cells decreased viability as well as proliferative ability. Flow cytometry analysis showed a lessen effect of the treatment on apoptosis. The gene expression analysis showed a reduction of RUNX2 expression in a dose-dependent manner and migration ability was reduced significantly in both treated cell lines. Our findings suggest that BEL β-trefoil can be considered a useful tool against malignancy due to its effect based on the simultaneous proliferation ability reduction as well as the inhibition of migration capacity on melanoma tumor cells.
doi:10.3892/or.2017.5493 pmid:28350114 fatcat:5obqvzxy65gqvfgrubhtkuyxfi